TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04815083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminolevulinic Acid Hydrochloride
Description: PD G 506 A for oral solution (aminolevulinic acid \[ALA\] hydrochloride \[HCl\] granules for oral solution) is administered as a single dose (20 mg/kg body weight) approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eagle V1.2 Imaging System
Description: Fluorescence imaging camera and associated accessories used to view and capture fluorescence and white light images and videos of the surgical cavity and excised tissue specimens during the surgical procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo is administered as a single dose approximately 3 hours (min 2 hours, max 4 hours) prior to anesthesia.
Study: NCT04840251

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Well-being review and rehabiliation
Description: For their well-being review, patients will meet with a physiotherapist specialist in PH and discuss:~* how they are~* what they can do for themselves~* what it is challenging for them to do~* how active they are~* if they have ever exercised before The physiotherapist will then make a referral to the most suitable rehabilitation service local to the patient e.g. rehabilitation classes, physiotherapy at home, weight-loss programmes.

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interviews
Description: Patients who have previously undergone rehabilitation will take part in a semi-structured interview to explore their experience and the impact it has had
Study: NCT05562570

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity intervention coupled with standard post-cancer directed treatment care
Description: AYACS will participate in a 16-week physical activity program. AYACS will be instructed to start with a session duration of \<15-min, three days per week at low intensity (e.g., activities expending \>1.5 to 3 METs or intensity \<5 on a scale of 0 to 10). Any type of physical activity will be acceptable. The program will be individualized, and activity increased according to patients' health status, results from the physical function assessment, and most recent week's achieved physical activities. The program will include support calls and texts from research staff (exercise physiologist). The program will be modified and adapted during support calls or texts, including frequency, intensity, time and type to maximize AYACS' success. AYACS will receive a Fitbit at the beginning of the intervention.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard post-cancer directed treatment care control
Description: AYACS in the control group will not participate in a 16-week physical activity program and will not receive support calls or texts. Physical activity advice according to the Exercise Guidelines for Cancer Survivors will be offered to AYACS following completion of 16-week follow-up. Moreover, AYACS will receive a Fitbit following completion of 16-week follow-up
Study: NCT05232916

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Normal Saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLSI-100
Description: 500 mcg/mL GP2 and 125 mcg/mL GM-CSF

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GLSI-100
Description: 500 mcg/mL GP2 and 125 mcg/mL GM-CSF
Study: NCT06404307

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-administration
Description: patients will self administer their antimicrobial treatment
Study: NCT06551519

Intervention type: OTHER
Intervention: ofatumumab
Description: This is an observational study. There is no treatment allocation. The decision to initiate ofatumumab will be based solely on clinical judgement.

Intervention type: OTHER
Intervention: DMT category 1
Description: This is an observational study. There is no treatment allocation. The decision to continue their current DMT will be based solely on clinical judgement.
Study: NCT04498754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia
Description: 8 sessions of treatment for insomnia.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Weekly phone contacts
Description: Weekly calls to monitor insomnia symptoms.
Study: NCT05543356

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tozinameran
Description: A single standard dose (30mcg) will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Elasomeran
Description: A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tozinameran
Description: A single standard dose (30mcg) will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Elasomeran
Description: A single standard dose (50mcg) of the intervention will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Pfizer-BioNTech
Description: A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Moderna
Description: A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg)will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Pfizer-BioNTech
Description: A single standard dose (BNT162b2 15μg + BNT162b2 OMI 15μg) will be administered on day 0 of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent Moderna
Description: A single standard dose (BNT162b2 15μg +BNT162b2 OMI 15μg) will be administered on day 0 of the study.
Study: NCT05765565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octaray multi-electrode catheter
Description: Newly designed multi-electrode catheter for creating 3D electroanatomical CARTO maps.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pentaray multi-electrode catheter
Description: Current standard multi-electrode catheter for creating 3D electroanatomical CARTO maps.
Study: NCT06657105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/LNG
Description: EE/LNG tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE/LNG
Description: EE/LNG tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baxdrostat
Description: Baxdrostat tablet will be administered orally.
Study: NCT04820868

Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection test

Intervention type: DEVICE
Intervention: Multi-cancer early detection test
Description: Blood collection and multi-cancer early detection test
Study: NCT05666583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: The intervention group is the group in which art therapy is applied. They receive chemotherapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: The intervention group is the group in which art therapy is applied. They receive chemotherapy.
Study: NCT05314400

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Full Gadoxetate-enhanced liver MRI
Description: Standard pulse sequences

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shortened Gadoxetate-enhanced liver MRI
Description: Fewer pulse sequences
Study: NCT05031884

Intervention type: DEVICE
Intervention: MGIR3-US
Description: MGIR3-US is an remote scanning robot which can do ultrasonic examinations.
Study: NCT05128981

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MI-CBT
Description: Education of MI and common reactions, Interoceptive exposure, Exposure in-vivo, Behavioral activation, Relapse prevention
Study: NCT05017857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RepetiveTranscrainal Magnetic Stimulation (rTMS)
Description: RepetiveTranscrainal Magnetic Stimulation (rTMS): rTMS is a non-invasive electromagnetic stimulation of the brain. A train of electric pulses is delivered at the same intensity over a set period of time to a targeted region of the brain. The current stimulates or suppresses neuronal activity based on the frequency and inter-train interval between the pulses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RepetiveTranscrainal Magnetic Stimulation (rTMS)
Description: RepetiveTranscrainal Magnetic Stimulation (rTMS): rTMS is a non-invasive electromagnetic stimulation of the brain. A train of electric pulses is delivered at the same intensity over a set period of time to a targeted region of the brain. The current stimulates or suppresses neuronal activity based on the frequency and inter-train interval between the pulses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Training (PST)
Description: Problem-Solving Training (PST) is a metacognitive strategy training in which patients are guided through a process of conscious self-assessment resulting in problem identification, generation of solutions, development of specific goals and action plans, and evaluation and revision of plans as needed. PST thus helps to circumvent impulsive or unrealistic problem-solving attempts that lead to failure, discouragement, and feelings of helplessness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Training (PST)
Description: Problem-Solving Training (PST) is a metacognitive strategy training in which patients are guided through a process of conscious self-assessment resulting in problem identification, generation of solutions, development of specific goals and action plans, and evaluation and revision of plans as needed. PST thus helps to circumvent impulsive or unrealistic problem-solving attempts that lead to failure, discouragement, and feelings of helplessness.
Study: NCT04995822

Intervention type: DEVICE
Intervention: hip arthroplasty
Description: Hip prosthesis surgery
Study: NCT05459727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Description: Non-surgical periodontal therapy includes basic oral hygiene instructions and full-mouth subgingival scaling and root planing under local anesthesia.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control periodontal treatment
Description: Control periodontal treatment includes basic oral hygiene instructions and full-mouth supragingival ultrasonic scaling.
Study: NCT05593965

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta TMS
Description: TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delta-beta TMS
Description: TMS will be delivered in a delta-beta pattern in which triplets of pulses delivered at 20 Hz (50 milliseconds between each pulse) are sent every 3 Hz (333 milliseconds between the start of each triplet).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma TMS
Description: TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta-gamma TMS
Description: TMS will be delivered in a theta-gamma pattern in which triplets of pulses delivered at 50 Hz (20 milliseconds between each pulse) are sent every 5 Hz (200 milliseconds between the start of each triplet).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic TMS
Description: TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arrhythmic TMS
Description: TMS will be delivered in an arrhythmic pattern in which pulses are delivered with a random inter-pulse interval. The number of pulses and duration is matched to that of the Delta-beta TMS and Theta-gamma TMS.
Study: NCT02385396

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic: myo-inositol and folic acid
Description: 4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
Study: NCT04942756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring
Description: FSL2 is an integrated continuous glucose monitoring (CGM) system that provides continuous glucose measurements every minute to provide glucose levels, trends and alerts. It is composed by a sensor and a reader. The Sensor, to apply on the back of the arm, continuously measures glucose concentration in interstitial fluid and has an 8-hour memory capacity. The Sensor is factory calibrated, does not require finger stick calibration and can be worn for up to 14 days.~The reader is a small handheld device that monitors glucose values in real-time to provide alerts and alarms which, when enabled, warn the user of Low Glucose, High Glucose or Signal Loss and prompt the user to scan the Sensor.~The FSL 2 System is CE mark, it is commercially available and in the current study it is being used in accordance with approved labeling. No modifications of FSL2 System have been performed for the utilization in the current study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The control group is represented by the usual standard way for blood glucose (BG) monitoring. The control group will use a lancing device for finger samples for collection of blood drop to be put in the test strips to be read in the Glucose meter. Lancing devices, lancets and test strips used in the comparison groups are CE marked and are used according to the user's instructions.~Monitoring and/or self-monitoring of blood glucose using glucose meters and test strips provides quantitative measurements of fingerstick blood glucose at a single point in time for patients and their healthcare providers to monitor the effectiveness of glycemic control and make more immediate treatment with the right dosage of insulin. The usual standard routine for blood glucose monitoring in patients with DM and with insulin therapy is represented by at least three finger pricks/die according to the usual standards routine of each center.
Study: NCT05613894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: (177Lu)-PSMA-617 will be administered every 6 weeks for up to 6 cycles per SOC. Oral Cabozantinib taken daily at home.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: (177Lu)-PSMA-617 will be administered every 6 weeks for up to 6 cycles per SOC. Oral Cabozantinib taken daily at home.
Study: NCT05727137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single shot adductor canal block
Description: Single shot adductor canal block on the the first and second postoperative day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous adductor canal block
Description: A catheter will be placed in the adductor canal and connected to a continuous patient-controlled analgesia pump.
Study: NCT06248450

Intervention type: OTHER
Group type: OTHER
Intervention: Medical yoga
Description: Medical yoga is a therapeutic form of Kundalini yoga led by a certified yoga instructor that uses different standardized yoga programs with a combination of physical postures, breathingexercises, and relaxation/meditation.

Intervention type: OTHER
Group type: OTHER
Intervention: Medical yoga
Description: Medical yoga is a therapeutic form of Kundalini yoga led by a certified yoga instructor that uses different standardized yoga programs with a combination of physical postures, breathingexercises, and relaxation/meditation.
Study: NCT05710341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water with added nitrate
Description: Water with added nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Water without added nitrate
Description: Water without added nitrate
Study: NCT05134792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin
Description: All pediatric burn patients allocated in group intra venous immunoglobulin admitted will receive 200 mg/kg IVIG once after their initial resuscitation before 48 hours passes of burn incident.
Study: NCT05128812

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLX
Description: Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PLX
Description: Intake of natural food supplement of vegetable origin based on lemon verbena extract (Lippia citriodora). To study the anxiolytic effects in subjects with high perceived stress levels and low sleep quality.
Study: NCT06774898

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom-molded lumbar-sacral orthosis
Description: A custom-molded lumbar-sacral orthosis made according to the Vésinet method associated with measures designed to enhance adherence based on goal-setting techniques (i.e. personalized advice, self-determination of the wearing time, hotline) techniques and monitoring of adherence using a temperature sensor chip to provide feedbacks to participants on the wearing time at follow-up visits, and usual care (i.e. a standardized prescription of 20 outpatient physiotherapy sessions including active self-correction, spinal muscle strengthening, spine and lower limb stretching and learning of home-based exercises).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Usual care consisting in a standardized prescription of 20 outpatient physiotherapy sessions including active self-correction, spinal muscle strengthening, spine and lower limb stretching and learning of home-based exercises
Study: NCT06770439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI343
Description: IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI343
Description: IBI343 is a recombinant anti-tight junction protein 18.2 monoclonal antibody - ecotecan conjugate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+Albumin-bound paclitaxel
Description: Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+Albumin-bound paclitaxel
Description: Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine+Albumin-bound paclitaxel
Description: Gemcitabine+ Albumin-bound paclitaxel is one of the recommended first line regime for advanced pancreatic cancer
Study: NCT06770270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pucotenlimab
Description: Pucotenlimab combined with long-course concurrent chemoradiotherapy, followed by two cycles of pucotenlimab combined with CAPOX, and then based on tumor response, TME surgery or a watch and wait strategy will be adopted.
Study: NCT05570084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silodosin
Description: Cap silodosin for medical expulsion therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Cap tamsulosin
Study: NCT06023147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: E-TACE
Description: The 100μm drug-loaded microspheres were loaded with 40mg-80mg anthracyclines at 1mL/2mL, and then combined with non-isoionic contrast agents to embolize the tumor supplying arteries, and then 250μm or 400μm drug-loaded microspheres were loaded with 1mL/2mL chemotherapy drugs to embolize the tumor supplying arteries at different grades and diameters.
Study: NCT05582460

Intervention type: DIAGNOSTIC_TEST
Intervention: Reporter Gene Assay
Description: Transcription factor reporter gene assay using luciferase

Intervention type: DIAGNOSTIC_TEST
Intervention: Reporter Gene Assay
Description: Transcription factor reporter gene assay using luciferase

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometry
Description: Flow Cytometry Analysis using the Sysmex UF-4000, analyzing for bacteria, mononuclear and polymorphonuclear cells, and red blood cell and white blood cell count.

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometry
Description: Flow Cytometry Analysis using the Sysmex UF-4000, analyzing for bacteria, mononuclear and polymorphonuclear cells, and red blood cell and white blood cell count.
Study: NCT05316922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Description: Levothyroxine is used to treat hypothyroidism (low thyroid function). This medicine is given when your thyroid does not produce enough of this hormone on its own.
Study: NCT06305416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 10mg/ml Injection
Description: Ranibizumab 10mg/ml Injection (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis
Description: Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
Study: NCT04944537

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT05888870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCT800 and Daratumumab
Description: SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SCT800
Description: SCT800 50IU/kg TIW alone
Study: NCT06242405

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-mesenchymal stem cells
Description: Umbilical cord mesenchymal stem cells injected through peripheral veins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: umbilical cord-mesenchymal stem cells
Description: Umbilical cord mesenchymal stem cells injected through peripheral veins
Study: NCT05737992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise in water
Description: Participants will do some exercises in water for 30-60 minutes. Exercises will be performed at a moderate exercise intensity (12-14 on the Borg Rate of Perceived (RPE) Scale).~All protocols are tailor-made based on each individual's needs and physical abilities.
Study: NCT02069626

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: compression time of the laparoscopic linear stapler

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: compression time of the laparoscopic linear stapler

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: compression time of the laparoscopic linear stapler